Medical device and regenerative medicine company TBYR Health has earned FDA clearance for its B3 gel system, a bioresorbable gel barrier that protects healing tissue planes and preserves mobility following tendon, ligament and skeletal muscle surgeries.
The gel, which is composed of a naturally derived extracellular matrix, helps to temporarily separate tissues during the bone healing phase, according to a June 9 news release.
It can be used for patients following both open and minimally invasive procedures. Commercial sales of the gel will begin by the end of 2025.
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.